Subsidiary’s 9-valent HPV vaccine receives marketing authorization in Thailand
August 12, 2026
Source: drugdu
26
Shanghai Securities News, China Securities Network, August 11 - Wantai Biopharmaceutical...Disclosure regarding the company's nine-valent HPV vaccineAnnouncement of Marketing Authorization in Thailand. The announcement states that the nine-valent human papillomavirus vaccine (Escherichia coli) independently developed by the company's wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has recently received approval from the Thai Food and Drug Administration.
The nine-valent HPV vaccine is a preventive biological product independently developed by Wantai Biological Pharmacy Enterprise Co., Ltd.This is my country's first and the world's second nine-valent HPV vaccine. It is mainly suitable for women aged 9-45 and covers seven high-risk HPV types (16/18/31/33/45/52/58) and two low-risk HPV types (6/11). It can prevent diseases caused by infection with the above-mentioned human papillomavirus types.
The company stated that the approval of the 9-valent HPV vaccine in Thailand marks the first overseas marketing authorization for this product, signifying that it is now qualified for export to the Thai market.
https://finance.eastmoney.com/a/202608113838150767.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Miraberon API Receives FDA Registration Approval August 12, 2026
- Signs Master Collaboration Agreement with Stella Pharma for the Commercialization of Boron Neutron Therapy Drugs August 12, 2026
- Medical device giant makes another move in spin-off. August 12, 2026
- Johnson & Johnson veterans lead the way as ICL giant embarks on its second growth curve. August 12, 2026
- Is Your Product Ready for Global Markets? Drugdu.com 10th Anniversary Overseas Promotion Readiness Program August 11, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
